Drug intelligence / Profile preview

verdiperstat

Development stage: Phase 3
Lead developer: Biohaven
Modality: Small Molecules
Administration: Oral

Overview

Verdiperstat is a first-in-class, potent, selective, brain-permeant small molecule that acts as an irreversible inhibitor of myeloperoxidase (MPO), an enzyme involved in the generation of reactive oxygen species and implicated in neuroinflammation and oxidative stress. By inhibiting MPO, verdiperstat is hypothesized to reduce microglial activation and neurodegeneration associated with diseases such as multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS). Verdiperstat has been investigated primarily for MSA but also for other neurodegenerative conditions. It has received Fast Track and Orphan Drug designations from the FDA and EMA due to unmet medical needs in MSA[3][5][4].

Brand names: verdiperstat
Other names: verdiperstat

Targets

MPO (Myeloperoxidase)

Beyond the preview

Go deeper on verdiperstat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on verdiperstat.

Explore the full profile